# Neurocrine Biosciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Neurocrine Biosciences, Inc). ## Overview Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders. It discovers, develops, and commercializes prescription therapies, with a commercial portfolio anchored by INGREZZA for tardive dyskinesia and Huntington’s chorea and CRENESSITY for classic congenital adrenal hyperplasia. ## Products & services • INGREZZA (valbenazine) for tardive dyskinesia and Huntington’s chorea • CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia • Elagolix-based products for endometriosis and uterine fibroids with AbbVie • Mid- to late-stage neuroscience pipeline candidates • Early-stage modalities: small molecules, peptides, proteins, antibodies, conjugates, gene therapies - **Commercial neurology products** (80%) — Approved therapies sold in the U.S. for movement disorders, primarily INGREZZA. - **Rare disease endocrinology** (10%) — CRENESSITY for classic congenital adrenal hyperplasia, launched in the U.S. in late 2024. - **Collaborative women’s health products** (5%) — Elagolix-based products for endometriosis and uterine fibroids commercialized with AbbVie. - **Pipeline and R&D programs** (5%) — Clinical and preclinical neuroscience assets across psychiatry, neurology, and endocrine disease. - INGREZZA (valbenazine) for tardive dyskinesia and Huntington’s chorea - CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia - Elagolix-based products for endometriosis and uterine fibroids with AbbVie - Mid- to late-stage neuroscience pipeline candidates - Early-stage modalities: small molecules, peptides, proteins, antibodies, conjugates, gene therapies ## Customers The company sells primarily to specialty pharmacy providers, wholesale distributors, and specialty distributors, reflecting a narrow channel model for specialty medicines. Its end customers are patients treated by neurologists, psychiatrists, endocrinologists, and rare-disease specialists, with prescribing driven by chronic disease management and high unmet need. INGREZZA is distributed through a limited specialty network, while CRENESSITY uses a single specialty pharmacy provider because of its rare-disease profile. - **Specialty pharmacy providers** (primary) — Dispense INGREZZA and CRENESSITY under tightly managed specialty distribution arrangements. - **Wholesale and specialty distributors** (primary) — Purchase and distribute INGREZZA in the U.S. through a limited network to support access and control. - **Neurology and psychiatry prescribers** (primary) — Prescribe INGREZZA for tardive dyskinesia and Huntington’s chorea based on efficacy and tolerability. - **Endocrinology and rare disease prescribers** (secondary) — Prescribe CRENESSITY for CAH patients needing a first-in-class treatment option. - **AbbVie collaboration partner** (secondary) — Commercializes elagolix-based women’s health products globally and shares economics under the collaboration. - Specialty pharmacies that dispense INGREZZA and CRENESSITY - Wholesale and specialty distributors handling limited-channel access - Neurologists and psychiatrists prescribing for movement disorders - Endocrinologists treating rare adrenal disorders like CAH - Patients with chronic, under-addressed neurological and endocrine diseases ## Geography Neurocrine’s commercial business is overwhelmingly U.S.-centric, with INGREZZA and CRENESSITY sold in the United States. Outside the U.S., INGREZZA is marketed in Japan and select Asian markets under partner arrangements, while elagolix rights are retained globally by AbbVie. This makes the company’s direct revenue base highly concentrated in one market, with limited international diversification. - U.S. is the core market for INGREZZA and CRENESSITY sales - INGREZZA is also marketed in Japan and select Asian markets by partners - AbbVie retains global commercialization rights to elagolix - Commercial operations and sales force are primarily U.S.-based - Single-market concentration increases exposure to U.S. pricing and reimbursement ## Strategy The company is focused on maximizing INGREZZA’s penetration, scaling CRENESSITY’s launch, and expanding commercial coverage in neurology, psychiatry, long-term care, and rare disease. At the same time, it is investing in a broader late-stage and early-stage pipeline so future launches can reduce dependence on a small number of products. The strategy combines near-term commercial execution with longer-term pipeline optionality. - **Maximize INGREZZA growth** (short-term) — INGREZZA is the main revenue engine and broader penetration supports near-term cash generation. - **Scale CRENESSITY launch** (short-term) — CRENESSITY adds a second commercial product and broadens the company beyond one franchise. - **Advance late-stage pipeline** (medium-term) — New approvals are needed to diversify revenue and reduce concentration risk. - **Broaden early-stage modality mix** (long-term) — A wider scientific platform increases the odds of future differentiated assets. - Expand INGREZZA reach in community and institutional settings - Scale CRENESSITY launch in endocrinology and rare disease - Increase sales force coverage and prescriber frequency - Advance late-stage assets in major depressive disorder and schizophrenia - Build a diversified pipeline across multiple modalities ## Risks The business depends heavily on successful commercialization of a small number of products, especially INGREZZA, so any slowdown in demand, access, or physician adoption would have an outsized impact. It also faces typical biopharma risks around clinical failure, regulatory delay, safety events, supplier dependence, and payer pressure on pricing and reimbursement. Customer concentration is material because a few specialty channel partners represent most gross product sales. - **Product concentration in INGREZZA** [high] — A large share of revenue comes from one commercial franchise, so any demand or access issue would materially affect results. - **Customer concentration** [high] — Four customers account for over 90% of gross product sales, increasing counterparty and channel risk. - **Clinical development failure** [high] — Pipeline assets may not prove safe or effective, which would reduce future growth options. - **Pricing and reimbursement pressure** [high] — Government and third-party payors can restrict coverage or pricing, limiting product uptake and margins. - **Supply chain and third-party supplier dependence** [medium] — The company relies on limited suppliers and logistics partners for product supply and distribution. - Heavy dependence on INGREZZA creates product concentration risk - CRENESSITY launch execution must succeed to diversify revenue - Four customers represent over 90% of gross product sales - Clinical candidates may fail, delay, or require more capital - Pricing, coverage, and reimbursement pressure can limit access - Supply interruptions or safety issues could disrupt commercialization ## Accounting Revenue recognition is a key judgment area because specialty drug sales require estimates for discounts, allowances, and other reserves that can move with gross sales and formulary access. The company also has collaboration economics, including royalties and milestones, that can create period-to-period volatility in reported results. In addition, share repurchases, stock compensation, uncertain tax positions, and fair-value changes in investments can affect comparability across periods. - **Revenue recognition and reserves** — Affects reported product revenue and gross margin - **Collaboration accounting** — Affects operating income and comparability - **Inventory and launch-related cost treatment** — Affects gross margin trajectory - **Uncertain tax positions** — Can materially affect tax expense in a given period - Revenue reserves for discounts and allowances affect net product sales - Specialty channel sales can create timing and estimate volatility - Collaboration royalties and milestones can swing quarterly results - Stock-based compensation and repurchases affect operating and equity items - Uncertain tax positions and tax law changes can alter tax expense --- *Last updated: 2026-04-28T20:28:35.483497+00:00*